Location History:
- Shinagawa-ku, JP (2010)
- Tokyo, JP (2016)
Company Filing History:
Years Active: 2010-2016
Title: Yutaka Midorikawa: Innovator in Cancer Diagnosis
Introduction
Yutaka Midorikawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer diagnosis through his innovative methods. With a total of two patents to his name, Midorikawa is recognized for his groundbreaking work in identifying cancer markers.
Latest Patents
Midorikawa's latest patents include a method for diagnosing cancer by detecting GPC3. This method provides a novel approach to diagnosing cancer by identifying soluble glypican 3 in a test sample. Additionally, he has developed a method for predicting and judging the recurrence of liver cancer after treatment. This method is characterized by measuring GPC3 contained in a test sample using an anti-GPC3 antibody.
Career Highlights
Midorikawa is associated with Perseus Proteomics Inc., where he continues to advance his research and innovations. His work has the potential to significantly impact cancer treatment and patient outcomes.
Collaborations
Midorikawa has collaborated with notable colleagues, including Hiroyuki Aburatani and Susumu Tokita. These partnerships have fostered a collaborative environment that enhances research and development in cancer diagnostics.
Conclusion
Yutaka Midorikawa's contributions to cancer diagnosis through his innovative patents highlight his role as a leading inventor in the field. His work not only advances scientific knowledge but also holds promise for improving patient care in oncology.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.